The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 24, 2021

Primary Completion Date

December 24, 2025

Study Completion Date

January 24, 2026

Conditions

Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC

Interventions

DRUG

Camrelizumab+S-1

Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.

Trial Locations (1)

RECRUITING

Lin Zhao, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER